GSK acquires IDRx and its rare cancer drug for $1B upfront

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held biotech IDRx for $1 billion upfront, bringing a rare cancer treatment into the British drugmaker's fold. If ...